Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Cardiac injury, as measured by troponin elevation, has been reported among hospitalized coronavirus disease 2019 (COVID-19) patients and portends a poor prognosis. However, how the dynamics of troponin elevation interplay with inflammation and coagulation biomarkers over time is unknown. We assessed longitudinal follow-up of cardiac injury, inflammation and coagulation markers in relation to disease severity and outcome.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We retrospectively assessed 2068 patients with laboratory-confirmed COVID-19 between January 29 and April 1, 2020 at Tongji Hospital in Wuhan, China. We defined cardiac injury as an increase in high sensitivity cardiac troponin-I (hs-cTnI) above the 99th of the upper reference limit. We explored the dynamics of elevation in hs-cTnI and the relationship with inflammation (interleukin [IL]-6, IL-8, IL-10, IL-2 receptor, tumor necrosis factor-α, C-reactive protein) and coagulation (d-dimer, fibrinogen, international normalized ratio) markers in non-critically ill versus critically ill patients longitudinally and further correlated these markers to survivors and non-survivors.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Median age was 63 years (first to third quartile 51–70 years), 51.4% of whom were women. When compared to non-critically ill patients (<em>N</em> = 1592, 77.0%), critically ill (defined as requiring mechanical ventilation, in shock or multiorgan failure) patients (<em>N</em> = 476, 23.0%), had more frequent cardiac injury on admission (30.3% vs. 2.3%, <em>p</em> < 0.001), with increased mortality during hospitalization (38.4% vs. 0%, p < 0.001). Among critically ill patients, non-survivors (<em>N</em> = 183) had a continuous increase in hs-cTnI levels during hospitalization, while survivors (<em>N</em> = 293) showed a decrease in hs-cTnI level between day 4 and 7 after admission. Specifically, cardiac injury is an independent marker of mortality among critically ill patients at admission, day 4–7 and 8–14. Consistent positive correlations between hs-cTnI and interleukin (IL)-6 on admission (<em>r</em> = 0.59), day 4–7 (<em>r</em> = 0.66) and day 8–14 (<em>r</em> = 0.61; all <em>p</em> < 0.001) and d-dimer (at the same timepoints <em>r</em> = 0.54; 0.65; 0.61, all p < 0.001) were observed. A similar behavior was observed between hs-cTnI and most of other biomarkers of inflammation and coagulation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Cardiac injury commonly occurs in critically ill COVID-19 patients, with increased levels of hs-cTnI beyond day 3 since admission portending a poor prognosis. A consistent positive correlation of hs-cTnI with IL-6 and d-dimer at several timepoints along hospitalization could suggest nonspecific cytokine-mediated cardiotoxicity.</p>

The Peak Levels of Highly Sensitive Troponin I Predicts In-Hospital Mortality in COVID-19 Patients with Cardiac Injury: a Retrospective Study.

Elevated High Sensitivity Cardiac Troponin T is Nonlinearly Associated with Poor Prognosis in Aging COVID-19 Patients: A Retrospective Study.

Elevated Cardiac Troponin I as a Mortality Predictor in Hospitalised COVID-19 Patients

Cardiac Troponin I Association with Critical Illness and Death Risk in 726 Seriously Ill COVID-19 Patients: A Retrospective Cohort Study.

Cardiac Troponin I Associated with Poor Prognosis and Death Risk in 726 Severe and Critical COVID-19 Patients: A Retrospective Cohort Study

Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease

High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19

Analysis of Influencing Factors Related to Elevated Serum Troponin I Level for COVID-19 Patients in Yichang, China.

Role of a lower cutoff of high sensitivity troponin I in identification of early cardiac damage in non-severe patients with COVID-19

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?

Cardiac Injury and Clinical Course of Patients With Coronavirus Disease 2019

Risk factors for myocardial injury in patients with coronavirus disease 2019 in China.

Factors associated with acute cardiac injury and their effects on mortality in patients with COVID-19

Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression

Association between peak troponin level and prognosis among patients admitted to intensive cardiovascular care unit

Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19

Elevated cardiac troponin I as a predictor of outcomes in COVID-19 hospitalizations: a meta-analysis

Cardiac Troponin T as the Underlying Risk Factor Associated With Disease Severity and Mortality in Patients With Coronavirus Disease 2019

Serial high sensitivity troponin sampling in patients with SARS-CoV-2 infection

Characteristics and Clinical Significance of Myocardial Injury in Patients with Severe Coronavirus Disease 2019